Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars

With the development of anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies, trastuzumab-based therapy has become the standard of care among patients with early or advanced HER2-positive breast cancer. However, real-world data have shown that up to a half of patients do not re...

Descripción completa

Detalles Bibliográficos
Autores principales: Uifălean, Alina, Ilieş, Maria, Nicoară, Raul, Rus, Lucia Maria, Hegheş, Simona Codruţa, Iuga, Cristina-Adela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321008/
https://www.ncbi.nlm.nih.gov/pubmed/30257528
http://dx.doi.org/10.3390/pharmaceutics10040168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321008/
https://www.ncbi.nlm.nih.gov/pubmed/30257528
http://dx.doi.org/10.3390/pharmaceutics10040168

Ejemplares similares